Kymera Therapeutics (KYMR) Q2 2024 earnings summary

Executive summary

• Advanced multiple first-in-class degrader programs in immunology and oncology, including IRAK4 (KT-474), STAT6 (KT-621), STAT3 (KT-333), MDM2 (KT-253), and TYK2 (KT-294), targeting large, underserved disease areas.

• Sanofi expanded KT-474 (IRAK4) Phase 2 trials in HS and AD after positive interim safety and efficacy review, aiming to accelerate pivotal trial readiness.

• KT-621 (STAT6) completed IND-enabling studies with no safety findings; Phase 1 trial to start in H2 2024.

• KT-253 (MDM2) and KT-333 (STAT3) oncology programs showed promising efficacy and tolerability in early clinical data; Phase 1a dose escalation to complete in H2 2024.

• No product sales to date; revenue derived from research collaborations, mainly with Sanofi.

Financial highlights

• Q2 2024 revenue was $25.7 million, all from the Sanofi collaboration, up from $16.5 million in Q2 2023.

• R&D expenses were $59.2 million, with $7.3 million in non-cash stock-based compensation; G&A expenses were $17.4 million, with $7.1 million in non-cash stock-based compensation.

• Net loss for Q2 2024 was $42.1 million, compared to $38.8 million in Q2 2023.

• Cash, cash equivalents, and marketable securities totaled $702.4 million as of June 30, 2024, providing runway into the first half of 2027.

• Impairment charge of $4.9 million related to facility exit in 2024.

Outlook and guidance

• Cash runway supports execution of multiple data readouts, including oncology proof-of-concept in 2024 and key immunology milestones in 2025.

• KT-474 Phase 2 results expected beyond the first half of 2025 due to trial expansion.

• KT-621 (STAT6) Phase 1 to start in H2 2024; KT-294 (TYK2) Phase 1 to initiate in 2025.

• KT-253 (MDM2) and KT-333 (STAT3) Phase 1a enrollment to complete in H2 2024, with data and next steps to follow.

• Expects to require additional funding for late-stage development and commercialization.